Anthrax R&D Pipeline Analysis Report, Q4 2020
Anthrax Pipeline Overview
The Q4 Anthrax pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Anthrax, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Anthrax Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Anthrax disease overview, Anthrax types, Anthrax symptoms, causes, and FDA/EMA approved treatment options.
Anthrax Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Anthrax indication. The report presents near-term and long-term pipeline development trends and potential insights.
Anthrax Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 23 companies. Business profiles and contact details of the companies actively perusing Anthrax pipeline are assessed.
Anthrax R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Anthrax discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Anthrax companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Anthrax pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Anthrax Pipeline Market News and Developments during 2020
The Anthrax industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Anthrax Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.
Scope and Coverage
The Q4 Anthrax pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Anthrax, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Anthrax Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Anthrax disease overview, Anthrax types, Anthrax symptoms, causes, and FDA/EMA approved treatment options.
Anthrax Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Anthrax indication. The report presents near-term and long-term pipeline development trends and potential insights.
Anthrax Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 23 companies. Business profiles and contact details of the companies actively perusing Anthrax pipeline are assessed.
Anthrax R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Anthrax discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Anthrax companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Anthrax pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Anthrax Pipeline Market News and Developments during 2020
The Anthrax industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Anthrax Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.
Scope and Coverage
- Anthrax pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates
- Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.
- Company-company partnerships, company-institute partnerships, and investment details of companies are included
- 23 companies are included including Altimmune Inc, Aphios Corp, Aradigm Corp, Biologics Resources LLC, BlueWillow Biologics, Crestone Inc, Dynavax Technologies Corp , Elusys Therapeutics Inc , Emergent BioSolutions Inc , GC Pharma, Greffex Inc, Hawaii Biotech Inc, iBio Inc, Innovative Biologics Inc, Integrated BioTherapeutics Inc, iNtRON Biotechnology Inc, Paratek Pharmaceuticals Inc, Protein Potential LLC, ProThera Biologics Inc, Soligenix Inc, Vast Therapeutics Inc, Venomyx Inc, VLP Biotech Inc,
- Disease overview, Pipeline trends, market analysis, and other developments
- Potential licensing/new business opportunities in Anthrax pipeline market
- Global coverage of companies and pipeline agents
- 2020 Trends, market analysis, and developments
- Potential growth opportunities
- Comprehensive details of drug candidates
- Drive pipeline research and commercial assessment
- Assess most promising drug candidates and stay ahead of the competition
- Strengthen your pipeline through identifying business expansion and acquisition opportunities
- Develop new candidates based on most focused targets and mechanism of actions
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. ANTHRAX PIPELINE TRENDS AND INSIGHTS
2.1 Dominant Phase type of Anthrax Pipeline, 2020
2.2 Most focused Mechanism of Action in Anthrax Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Anthrax pipeline
2.5 Active Companies Developing Anthrax pipeline
3. ANTHRAX DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. ANTHRAX PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS
4.1 Altimmune Inc
Aphios Corp
Aradigm Corp
Biologics Resources LLC
BlueWillow Biologics
Crestone Inc
Dynavax Technologies Corp
Elusys Therapeutics Inc
Emergent BioSolutions Inc
GC Pharma
Greffex Inc
Hawaii Biotech Inc
iBio Inc
Innovative Biologics Inc
Integrated BioTherapeutics Inc
iNtRON Biotechnology Inc
Paratek Pharmaceuticals Inc
Protein Potential LLC
ProThera Biologics Inc
Soligenix Inc
Vast Therapeutics Inc
Venomyx Inc
VLP Biotech Inc
5. ANTHRAX PIPELINE DRUG PROFILES
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. ANTHRAX PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020
7. APPENDIX
7.1 About the Publisher
7.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2. ANTHRAX PIPELINE TRENDS AND INSIGHTS
2.1 Dominant Phase type of Anthrax Pipeline, 2020
2.2 Most focused Mechanism of Action in Anthrax Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Anthrax pipeline
2.5 Active Companies Developing Anthrax pipeline
3. ANTHRAX DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. ANTHRAX PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS
4.1 Altimmune Inc
Aphios Corp
Aradigm Corp
Biologics Resources LLC
BlueWillow Biologics
Crestone Inc
Dynavax Technologies Corp
Elusys Therapeutics Inc
Emergent BioSolutions Inc
GC Pharma
Greffex Inc
Hawaii Biotech Inc
iBio Inc
Innovative Biologics Inc
Integrated BioTherapeutics Inc
iNtRON Biotechnology Inc
Paratek Pharmaceuticals Inc
Protein Potential LLC
ProThera Biologics Inc
Soligenix Inc
Vast Therapeutics Inc
Venomyx Inc
VLP Biotech Inc
5. ANTHRAX PIPELINE DRUG PROFILES
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. ANTHRAX PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020
7. APPENDIX
7.1 About the Publisher
7.2 Sources and Research Methodology
